Minnesota is currently home to 2065 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Molecular Epidemiology of Pediatric Germ Cell Tumors
NCT05564026
Recruiting
A Non-Therapeutic Study that aims to establish a cohort of GCT survivors to understand short term and long-term adverse effects of treatment and to conduct molecular analyses to improve risk stratification.
Gender:
ALL
Ages:
All
Trial Updated:
09/27/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Germ Cell Tumor, Germinoma, Teratoma, Embryonal Carcinoma, Yolk Sac Tumor, Choriocarcinoma, Mixed Germ Cell Tumor, Late Effects, Pediatric Germ Cell Tumor
Register for Updates
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
NCT05172973
Recruiting
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
09/27/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Aortic Valve Insufficiency, Aortic Valve Stenosis
Register for Updates
Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
NCT03929601
Recruiting
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab-pvvr compared to those treated with Rituximab-pvvr and placebo 24 months after enrollment.
Gender:
ALL
Ages:
Between 8 years and 45 years
Trial Updated:
09/27/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Type 1 Diabetes Mellitus
Register for Updates
A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM
NCT05695391
Recruiting
This is an interventional, prospective, international, multicenter, single-arm, Phase 3, and sequential efficacy and safety study in adolescents and adults with congenital hemophilia A or B with inhibitors to factor VIII (FVIII) or factor IX (FIX) undergoing elective major surgical procedures.
Gender:
MALE
Ages:
Between 12 years and 65 years
Trial Updated:
09/26/2024
Locations: M Health Fairview Center for bleeding and Clotting disorders, Minneapolis, Minnesota
Conditions: Hemophilia
Register for Updates
Olorofim Aspergillus Infection Study
NCT05101187
Recruiting
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Invasive Aspergillosis
Register for Updates
A Study to Evaluate Breathing Muscle Training in Cardiac Rehab
NCT04984473
Recruiting
The purpose of this study is to understand if breathing muscle training combined with cardiac rehabilitation influences the blood flow and blood pressure response during exercise.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Healthy, Heart Failure
Register for Updates
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
All
Trial Updated:
09/26/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
Assessment of Usability and Satisfaction With a Take-home Device Presenting Sound and Body Stimulation for Back Pain
NCT06619418
Recruiting
Pain symptoms can have a variety of ways to be treated, from medications to physical therapy, with several options being available to patients. However, no one treatment may work for all people who experience pain, especially cLBP. The purpose of this study is to measure the compliance, usability, and satisfaction of an at-home, multi-modal stimulation device in a diverse population of people with chronic lower back pain (cLBP). The multi-modal device will include a combination of electrical sti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Chronic Lower Back Pain
Register for Updates
Clinical Trial of Concomitant Hip Arthroscopy During PAO
NCT03181048
Recruiting
The study will assess the outcomes of patients treated with concomitant hip arthroscopy at the time of periacetabular osteotomy (PAO) for patients with hip dysplasia compared with patients treated with PAO alone.
Gender:
ALL
Ages:
Between 15 years and 55 years
Trial Updated:
09/25/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Hip Dysplasia
Register for Updates
Endogenous Pain Inhibition Deficiency in Chronic TMD Pain
NCT06617494
Recruiting
Temporomandibular disorders (TMDs) involve a range of conditions with varied causes, affecting a large portion of the U.S. population and posing challenges for diagnosis and management, especially in chronic cases. Despite advances in understanding TMD pathophysiology, the role of central sensitization, particularly deficient endogenous pain inhibition, remains unclear. The conditioned pain modulation (CPM) test, used to assess pain inhibition in chronic TMD pain, has produced inconsistent resul... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
09/24/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Chronic Temporomandibular Disorders (TMD)
Register for Updates
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
NCT06238648
Recruiting
This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epcoritamab is a bispecific antibody. It works by simultaneously attaching to a molecule called CD20 on cancerous B-cells and a molecule called CD3 on effector T-cells, which are a type of immune cell. When epcoritamab binds to CD20 and CD3, it brings t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Register for Updates
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
NCT05721248
Recruiting
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
Register for Updates